Skip to main content
Erschienen in: International Journal of Hematology 4/2014

01.04.2014 | Case Report

An indeterminate result of QuantiFERON-TB Gold In-Tube for miliary tuberculosis due to a high level of IFN-γ production

verfasst von: Sho Hangai, Akihide Yoshimi, Atsuko Hosoi, Keisuke Matsusaka, Motoshi Ichikawa, Masashi Fukayama, Mineo Kurokawa

Erschienen in: International Journal of Hematology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

The QuantiFERON-TB Gold In-Tube® test has excellent specificity for Mycobacterium tuberculosis. However, diagnosis of miliary tuberculosis remains challenging, and the interpretation of QuantiFERON® results in immunocompromised individuals has not been fully established. Here, we present a patient with military tuberculosis who showed an indeterminate QuantiFERON® result. A 76-year-old male presented with fever and pancytopenia. Radiological tests did not show the classical miliary pattern. Acid-fast staining and polymerase chain reaction of several specimens were negative for M. tuberculosis. The QuantiFERON® responses were indeterminate on two separate tests, as interferon-γ (IFN-γ) concentration was high in the negative control. The patient did not respond to anti-microbiological therapy, and developed sepsis and disseminated intravascular coagulation, leading to lethal intracranial hemorrhage. An autopsy showed miliary tuberculosis and aplastic anemia. A literature review suggests a tendency towards indeterminate or false-negative QuantiFERON® results in immunocompromised individuals or patients with miliary tuberculosis due to low production of IFN-γ. Our patient, however, showed substantial amounts of IFN-γ despite lymphocytopenia, which has not been reported in the literature. The present case suggests that indeterminate results of QuantiFERON® should be interpreted with caution, as IFN-γ production in patients with miliary tuberculosis can vary significantly, even with sustained lymphocytopenia.
Literatur
1.
Zurück zum Zitat Sharma SK, Mohan A, Sharma A, Mitra DK. Miliary tuberculosis: new insights into an old disease. Lancet Infect Dis. 2005;5:415–30.PubMedCrossRef Sharma SK, Mohan A, Sharma A, Mitra DK. Miliary tuberculosis: new insights into an old disease. Lancet Infect Dis. 2005;5:415–30.PubMedCrossRef
2.
Zurück zum Zitat Ray S, Talukdar A, Kundu S, Khanra D, Sonthalia N. Diagnosis and management of miliary tuberculosis: current state and future perspectives. Ther Clin Risk Manag. 2013;9:9–26.PubMedCentralPubMedCrossRef Ray S, Talukdar A, Kundu S, Khanra D, Sonthalia N. Diagnosis and management of miliary tuberculosis: current state and future perspectives. Ther Clin Risk Manag. 2013;9:9–26.PubMedCentralPubMedCrossRef
3.
Zurück zum Zitat Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med. 1999;2000(161):1376–95. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med. 1999;2000(161):1376–95.
4.
Zurück zum Zitat Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007;146:340–54.PubMedCrossRef Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007;146:340–54.PubMedCrossRef
5.
Zurück zum Zitat Aichelburg MC, Rieger A, Breitenecker F, Pfistershammer K, Tittes J, Eltz S, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis. 2009;48:954–62.PubMedCrossRef Aichelburg MC, Rieger A, Breitenecker F, Pfistershammer K, Tittes J, Eltz S, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis. 2009;48:954–62.PubMedCrossRef
6.
Zurück zum Zitat Tozlu M, Kalyoncu U, Alp S, Unal S, Calguneri M. Diagnostic accuracy of Quantiferon TB test for patients with SLE and miliary tuberculosis. Rheumatol Int. 2009;29:1395–6.PubMedCrossRef Tozlu M, Kalyoncu U, Alp S, Unal S, Calguneri M. Diagnostic accuracy of Quantiferon TB test for patients with SLE and miliary tuberculosis. Rheumatol Int. 2009;29:1395–6.PubMedCrossRef
7.
Zurück zum Zitat Kobashi Y, Fukuda M, Yoshida K, Oka M. An indeterminate QuantiFERON TB-2G response for miliary tuberculosis, due to severe pancytopenia. J Infect Chemother. 2007;13:414–7.PubMedCrossRef Kobashi Y, Fukuda M, Yoshida K, Oka M. An indeterminate QuantiFERON TB-2G response for miliary tuberculosis, due to severe pancytopenia. J Infect Chemother. 2007;13:414–7.PubMedCrossRef
8.
Zurück zum Zitat Raby E, Moyo M, Devendra A, Banda J, De Haas P, Ayles H, et al. The effects of HIV on the sensitivity of a whole blood IFN-gamma release assay in Zambian adults with active tuberculosis. PLoS ONE. 2008;3:e2489.PubMedCentralPubMedCrossRef Raby E, Moyo M, Devendra A, Banda J, De Haas P, Ayles H, et al. The effects of HIV on the sensitivity of a whole blood IFN-gamma release assay in Zambian adults with active tuberculosis. PLoS ONE. 2008;3:e2489.PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Tsiouris SJ, Coetzee D, Toro PL, Austin J, Stein Z, El-Sadr W. Sensitivity analysis and potential uses of a novel gamma interferon release assay for diagnosis of tuberculosis. J Clin Microbiol. 2006;44:2844–50.PubMedCentralPubMedCrossRef Tsiouris SJ, Coetzee D, Toro PL, Austin J, Stein Z, El-Sadr W. Sensitivity analysis and potential uses of a novel gamma interferon release assay for diagnosis of tuberculosis. J Clin Microbiol. 2006;44:2844–50.PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Jung SH, Bae SY, Ahn JS, Kang SJ, Yang DH, Kim YK, et al. Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens. Int J Hematol. 2013;97:382–7.PubMedCrossRef Jung SH, Bae SY, Ahn JS, Kang SJ, Yang DH, Kim YK, et al. Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens. Int J Hematol. 2013;97:382–7.PubMedCrossRef
Metadaten
Titel
An indeterminate result of QuantiFERON-TB Gold In-Tube for miliary tuberculosis due to a high level of IFN-γ production
verfasst von
Sho Hangai
Akihide Yoshimi
Atsuko Hosoi
Keisuke Matsusaka
Motoshi Ichikawa
Masashi Fukayama
Mineo Kurokawa
Publikationsdatum
01.04.2014
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 4/2014
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-014-1504-3

Weitere Artikel der Ausgabe 4/2014

International Journal of Hematology 4/2014 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.